Cannabis use during pregnancy: little known about impact on child or maternal health


Cannabis is the most commonly used recreational drug, with research suggesting that approximately 3.8% of the world’s population consumed the drug in 2014 (UNODC, World Drug Report 2016), a number which has remained stable in recent years.

In spite of high levels of usage, the drug has not historically been viewed as a public health risk. Research conducted in recent years has however shown that regular cannabis use is associated with a range of poor physical and mental health outcomes and social issues (Hoch, 2015). Despite these findings, policy and law has become more lenient with regards to the drug, particularly in the USA where there are currently 24 states where cannabis is legal for medical use, and four states where it is legal to use recreationally.

The use of cannabis during pregnancy is an important issue, especially in light of the known adverse effects of long-term use in adults. A report published in 2015 by The American College of Obstetricians and Gynecologists found that between 48-60% of existing female cannabis users continue to use the drug while pregnant. In addition to existing users, there are also reported cases where expectant mothers are using cannabis to reduce the symptoms of morning sickness as an alternative to prescription pharmaceuticals. Overall it is estimated that in the US between 2-5% of women use cannabis while pregnant, with this number rising to 15-28% in women from low socioeconomic backgrounds (The American College of Obstetricians and Gynecologists, 2015).

There is research to suggest that smoking cannabis during pregnancy may have adverse effects on both the developing child and the mother. However, the existing research base is small and the findings are inconsistent. Thus, the aim of this paper was to systematically review research that investigates the effects of prenatal cannabis use on mothers and offspring, and conduct a meta-analysis to elucidate overall effects.

A 2015 US report found that about half of existing female cannabis users continue to use the drug when pregnant.

A 2015 US report found that about half of existing female cannabis users continue to use the drug when pregnant.


A search was conducted for studies published in peer reviewed journals that:

  • Employed a randomised controlled trial, case-controlled, cross-sectional or cohort design
  • Investigated the effects of prenatal use of cannabis during pregnancy on maternal, fetal, perinatal and neonatal outcomes up to 6 weeks postpartum.

Papers were excluded if participants reported other illicit drug use, but were not excluded for concurrent tobacco or alcohol use (as there were few papers where this was controlled for). In total, 24 publications were identified, and a mean difference meta-analysis and odds ratio meta-analyses were conducted.


The main findings were:

  • There was only one statistically significant maternal outcome in the meta-analysis, which showed that mothers who used cannabis during pregnancy had increased odds of anaemia
  • Infants whose mother used cannabis during pregnancy showed:
    • a significant reduction in birth weight
    • higher odds of low birth weight
    • a significant decrease in gestational length
    • were more likely to need placement in an intensive care unit or neonatal intensive care unit
  • No other significant findings were found for other child outcomes.

The authors note that due to inconsistent results and issues with individual study methodology, these findings should be viewed with caution.

The quality of research in this field is in serious need of improvement.

The quality of research in this field is in serious need of improvement.


  • The results of this study suggest that mothers who use cannabis during pregnancy have increased odds of anaemia, which is a risk of other poor outcomes in itself
  • The link shown between lower birth weight and prenatal exposure to cannabis is an important one. Low birth weight is a risk factor for a host of other serious poor outcomes, including neurodevelopmental problems and physical illness (Hack, 2005)
  • It should be noted that these outcomes (in particular admittance to an intensive care unit) not only burden the infant and their family, but also financially burden the healthcare services that support them.

Strengths and limitations

The authors’ most striking conclusion is that there is a lack of high quality research in this area. For example, there is very little research where participants only used cannabis, in most studies concurrent alcohol and tobacco use was common. The links between alcohol and tobacco and some of the outcomes listed in this review (including low birth weight) are well established. It is therefore not clear if the effects shown in these studies were as a result of cannabis use, or a consequence of tobacco and alcohol use.

The researchers also note that there was very little overlap between maternal outcomes collected and that these outcomes were not always standardised. There was also a reliance on self-reported cannabis use which, due to social desirability, could lead to lower reported cannabis use in the sample.

High quality studies that address the above issues may lead to more conclusive links being found between cannabis use and maternal and infant outcomes.


This is an important and timely systematic review and meta-analysis, which has nicely summarised our current understanding of the links between prenatal exposure to cannabis and maternal and infant outcomes. The paper describes why the effects of cannabis on maternal and infant outcomes are still relatively unknown, and the need for more high quality research in the field.

However it is important to consider that a lack of concrete conclusions should not be enough to down-play the risks to expectant mothers. Even with the tentative conclusions we can draw from this meta-analysis in mind, paired with what we know about the effects of cannabis on adults, it is clear that mothers and clinicians should err on the side of caution when considering the use of cannabis during pregnancy.

Whilst we're uncertain about the risks of cannabis consumption during pregnancy, it makes sense to err on the side of caution. 

Whilst we’re uncertain about the risks of cannabis consumption during pregnancy, it makes sense to err on the side of caution.


Primary paper

Gunn JKL, Rosales CB, Center KE, Nuñez A, Gibson SJ, Christ C, Ehiri JE. (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysisBMJ Open. 6, 1-8.

Other references

United Nations Office on Drugs and Crime. World Drugs Report 2016. United Nations publication, 2016.

Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U & Preuss UW. (2015) Risks Associated With the Non-Medicinal Use of CannabisDeutsches Ärzteblatt International. 112 (16), 271-8.

The American College of Obstetricians and Gynecologists, Marijuana Use During Pregnancy And Lactation. 2016. Print. Committee Opinion No 637.

Hack M, Klein NK & Taylor HG. (2005). Long-term developmental outcomes of low birth weight infants. Future Child. 5 (1), 176-96. [PubMed abstract]

Photo credits


Share on Facebook Tweet this on Twitter Share on LinkedIn Share on Google+
Mark as read
Create a personal elf note about this blog
Profile photo of Ellen Grimas

Ellen Grimas

Ellen completed her undergraduate degree in Psychology at the University of Exeter in 2013. During this time she worked part time as a Research Assistant on the Netmums Helping with Depression Study, a trial of a supported online Behavioural Activation treatment for postnatal depression (PND). Following her BSc, Ellen went on to work for the charity Rethink Mental Illness as a Mental Health Recovery Worker in a crisis house. She joined the Centre for Mental Health at Imperial College London in August 2014. She is currently working on the Healthy Start, Happy Start trial, a large scale RCT to evaluate an early intervention programme for young children with behavioural problems. Alongside this she is undertaking a PhD in Clinical Medicine at Imperial College supervised by Dr Paul Ramchandani and Dr Christine O'Farrelly. Her research is investigating coparenting behaviour as a risk factor in the development of child psychopathology. Research group website:

More posts - Website

Follow me here –